Semax Peptide | Loti Labs

Premium USA-Made Research Compounds

Browse lab-tested peptides, research liquids, capsules and more.

Table of Contents

Semax Peptide: Neurotrophic Research, Cognitive Studies & Laboratory Applications

For laboratory and research use only. Not for human consumption.

One intranasal dose. 50 μg/kg. That’s all it took. Within hours, BDNF mRNA in the hippocampus tripled. TrkB phosphorylation climbed 1.6-fold. A single administration.

Data like that is why Semax went from a niche Russian neuropeptide to one of the most studied nootropic compounds in neuroscience research. It’s a seven-amino-acid synthetic peptide (Met-Glu-His-Phe-Pro-Gly-Pro) derived from the ACTH(4–10) fragment. The Pro-Gly-Pro tail bolted onto the C-terminus makes it resistant to enzymatic chewing — and, it turns out, carries independent pharmacological activity of its own. Three-plus decades in research. Registered in Russia since 1996. Preclinical data covering BDNF, NGF, dopamine, serotonin, stroke neuroprotection, and immune signaling. That list sounds implausible for one peptide. Then you read the published papers and realize every pathway has data behind it.

Looking for Premium Research Compounds?

🧪 Peptides 💧 Research Liquids 💊 Capsules 🛒 Full Catalog

What Is Semax?

Seven amino acids. MEHFPGP. A synthetic analogue of the ACTH(4–10) fragment — that’s the stretch of adrenocorticotropic hormone between residues 4 and 10 that carries the CNS activity. The full ACTH molecule stimulates cortisol release. Semax doesn’t. Zero hormonal activity. All the brain effects, none of the adrenal stimulation.

Sequence: Met-Glu-His-Phe-Pro-Gly-Pro (MEHFPGP)
Classification: Synthetic ACTH(4–10) analogue with PGP extension
Molecular Weight: ~813.97 g/mol
Route (preclinical): Predominantly intranasal
Status: Investigational research compound; not FDA-approved

The PGP tail isn’t just armor against peptidases. It has independent biological activity — immunomodulatory signaling and improved blood-brain barrier penetration after intranasal delivery. You’re looking at a bifunctional molecule: ACTH(4–7) activity paired with PGP-mediated effects (PMC11498467). Two pharmacological programs in one peptide.

Development Story

1980s. Nikolay Myasoedov’s lab at the Institute of Molecular Genetics, Russian Academy of Sciences. Same institute that produced Selank. The goal: take the ACTH(4–10) fragment — already known to have CNS effects — and make it last long enough to be useful. Intranasal delivery. No hormonal baggage.

They succeeded. By 1996, Semax was registered in the Russian Federation for post-stroke recovery, optic nerve atrophy, and cognitive impairment. It’s still available there and in Ukraine as a nasal spray. Three decades of published research, mostly in Russian-language journals — though international work is picking up as transcriptomic and proteomic tools make Semax’s multi-pathway effects easier to characterize at a molecular level.

No FDA approval. No EMA approval. In the West, Semax remains strictly a research compound. That hasn’t slowed the accumulation of preclinical data.

Chemistry and Structure

Start with ACTH’s core pharmacophore — the His-Phe sequence at positions 6-7 that drives melanocortin-related CNS activity. Semax modifies the surrounding residues (swapping Arg-Trp for Pro-Gly-Pro) so you keep the brain activity but eliminate adrenal stimulation. The Met-Glu N-terminus and the PGP C-terminus are what make Semax a distinct compound rather than just an ACTH fragment.

That PGP tail warrants attention. Studies on PGP alone show it activates neurotrophin transcription in ischemic brain tissue (PMC11498467). So the C-terminal extension isn’t passive — it’s an active pharmacological component that contributes to Semax’s neuroprotective profile independently of the ACTH-derived core.

Mechanism of Action: BDNF Is the Headline, But Not the Whole Story

Semax’s nootropic effects run through multiple pathways. BDNF/TrkB gets the most attention. Rightfully — the numbers are striking. But there’s more happening underneath.

BDNF and TrkB: The Core Pathway

The landmark data comes from a Brain Research paper (PMID: 16996037). Single intranasal dose, 50 μg/kg, in rodents. Hippocampal effects:

1.4-fold increase in BDNF protein
1.6-fold increase in TrkB phosphorylation
3-fold increase in exon III BDNF mRNA
2-fold increase in TrkB mRNA

One dose. Hours. That’s not a marginal effect — that’s a robust neurotrophic signal.

Binding studies went further: tritium-labeled Semax binds specific sites in rat basal forebrain with a K_D of 2.4 ± 1.0 nM and B_MAX of 33.5 ± 7.9 fmol/mg protein. Calcium-dependent. Reversible. That’s receptor-mediated binding, not nonspecific membrane interaction. And the BDNF response was region-specific — basal forebrain yes, cerebellum no. Targeted, not diffuse.

NGF and Neurotrophin-3

BDNF isn’t alone. In permanent middle cerebral artery occlusion (pMCAO) models, Semax upregulated NGF, NT-3, and their high-affinity receptors (TrkA, TrkB, TrkC). Timing and magnitude varied by brain region and how long since the ischemic event (PMC11498467). That broad neurotrophin-activating profile is unusual — most compounds in this space hit one pathway, maybe two. Semax hits the full set.

Dopamine and Serotonin

Eremin et al. (2005) documented that Semax increases striatal dopamine release and amplifies locomotor responses to d-amphetamine. Serotonergic modulation runs alongside. These monoamine effects feed directly into what behavioral testing measures as improved attention, motivation, and cognitive processing. BDNF sets the stage for neuroplasticity; dopamine and serotonin handle the real-time performance effects.

Preclinical Findings: Stroke, Cognition, and Gene Expression

Neuroprotection in Ischemia

This is some of the most compelling Semax data. Genome-wide expression profiling (Illumina RatRef-12 BeadChip) on cortical tissue from pMCAO rodents (PMC3987924):

At 3 hours post-stroke, Semax shifted expression of genes controlling immune cell activity and migration. By 24 hours, immune-response genes accounted for over 50% of all expression changes. Immunoglobulin genes were the most heavily upregulated group — several showing the highest expression amplitude of any transcript affected. Vascular system and intracellular calcium genes also moved.

A 2020 ischemia-reperfusion study confirmed the pattern from the protein side: Semax compensated for mRNA expression disruption during ischemia-reperfusion, suppressed inflammatory and cell-death processes, and activated recovery pathways at both transcriptome and protein levels. Not just gene expression changes — actual neuroprotective biology.

Cognitive Effects

Consistent results across multiple rodent behavioral paradigms. Semax enhances conditioned avoidance reactions and learning-dependent behaviors. Memory consolidation improves. Attention sharpens. These cognitive gains correlate with measured BDNF/TrkB increases in the hippocampus — mechanism and behavioral outcome lining up.

Resting-state fMRI work adds anatomical context: Semax produces measurable changes in default mode network architecture, specifically the medial frontal cortex subcomponent. You can see the compound’s effects on functional brain connectivity, not just isolated neurotransmitter measures.

Transcriptomic Depth

In the intact rat hippocampus (no ischemia, no pathology), Semax modulates genes involved in intracellular signaling: MAPK10, APP (amyloid precursor protein), fibronectin 1. This tells you something important — Semax isn’t only active under pathological conditions. It engages fundamental neuroplasticity and tissue homeostasis pathways in normal brain tissue too.

For labs studying neuropeptide signaling in cognition, DSIP and Pinealon are relevant comparisons.

Semax vs. Selank: Same Lab, Different Compounds

Both heptapeptides. Both from Myasoedov’s institute. Both share the PGP tail. But they do fundamentally different things.

Parameter	Semax	Selank
Parent	ACTH(4–10)	Tuftsin
Sequence	MEHFPGP	TKPRPGP
Primary Profile	Nootropic, neurotrophic, neuroprotective	Anxiolytic, immunomodulatory
Core Mechanism	BDNF/NGF upregulation, DA/5-HT modulation	GABA_A modulation, enkephalinase inhibition
BDNF Effect	Primary: 1.4× protein, 3× mRNA	Secondary: moderate, state-dependent
Cognitive Effects	Pronounced — attention, memory, avoidance learning	Moderate — mainly under stress conditions
Anxiolytic	Modest mood stabilization	Strong — benzo-equivalent without sedation
Russia Approval	1996	2009
Gene Expression	24 vascular genes, extensive immune modulation in ischemia	45 neurotransmission genes in frontal cortex

Quick version: Semax is the cognition compound. Selank is the anxiety compound. Both touch neurotrophins. Both modulate the immune system. But their primary research domains don’t overlap much. Some labs run them in combination — hypothesizing complementary effects on cognition under stress — though controlled data on combination protocols is still limited.

Safety Profile

Across every published preclinical study — clean. No hormonal effects despite the ACTH heritage. Semax does not trigger corticosterone or cortisol release. At intranasal doses of 50–250 μg/kg in rodents, nothing concerning showed up.

Protocol design notes:

The ACTH parentage is misleading — hormonal activity was specifically engineered out. No adrenal stimulation
Binding is calcium-dependent. Control for that in your in vitro work or you’ll get artifacts
BDNF response is region-specific: basal forebrain and hippocampus respond strongly, cerebellum doesn’t budge. Sample your tissues accordingly
PGP tail makes Semax resistant to aminopeptidases. That changes your PK modeling assumptions

Procurement basics: demand third-party COAs, HPLC purity data, and mass spec confirmation. Peptide aggregation and impurity risks are real with any research peptide.

Regulatory Status

Russia/Ukraine: Registered. Available as nasal spray for post-stroke recovery, optic nerve atrophy, and cognitive impairment. One of the few peptides with actual regulatory approval for CNS indications anywhere.

United States: Not FDA-approved for any indication. Research compound only. Not a controlled substance.

EU/International: Not EMA-approved. Classified as investigational.

Research Availability

Semax 5mg from Loti Labs — third-party verified purity, suitable for in vitro and in vivo work. Researchers doing comparative neuropeptide pharmacology should also consider Selank 10mg for parallel or combination studies.

Conclusion

Three decades of data and counting. A single dose triples hippocampal BDNF mRNA. Genome-wide profiling shows immune-response gene activation comprising over half of all ischemia-affected transcripts. Region-specific neurotrophic effects verified by binding studies with nanomolar affinity. Cognitive enhancement documented across multiple behavioral paradigms.

Semax isn’t a simple nootropic. It’s a multi-pathway neurotrophic compound — BDNF, NGF, NT-3, dopamine, serotonin, and immune modulation — that happens to also improve cognition. The receptor it binds to hasn’t been definitively identified yet (K_D = 2.4 nM, but the molecular target remains unknown). Neurodegenerative disease models are largely unexplored. And combination protocols with Selank and other neuropeptides are barely off the ground.

There’s a lot of open territory here. For neuroscience labs with the right tools, Semax is one of the more interesting compounds to put under the microscope.